CO/chemosensitization/antiangiogenesis synergistic therapy with H<sub>2</sub>O<sub>2</sub>-responsive diselenide-containing polymer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33631653.
- Also identified by DOI 10.1016/j.biomaterials.2021.120721.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Carbon monoxide (CO) therapy and antiangiogenesis therapy (AAT) are regarded as promising approaches for cancer treatment. However, the poor tumor targeting ability and inevitable side effects prevent their clinical application. In this study, we developed H<sub>2</sub>O<sub>2</sub>-responsive diselenide-containing micelles that combined CO therapy with chemosensitization therapy and AAT in a single system. Under the interaction of intratumoral H<sub>2</sub>O<sub>2</sub>, CO and gemcitabine (GEM) were released in situ from the micelles to reduce side effects, and CO significantly sensitized the chemotherapeutic effect of GEM by elevating the level of reactive oxygen species (ROS) in human gastric cancer AGS cells. Furthermore, diselenide bonds in the micelles were oxidized to seleninic acid in organic form, which suppressed the expressions of vascular endothelial growth factor (VEGF) and matrix metalloproteinase-2 (MMP-2) to realize AAT. This study provides an integrated solution to combine CO therapy with chemosensitization therapy and AAT together with good biocompatibility.
Medical subject headings
- Hydrogen Peroxide
- Polymers